VIRX
Viracta Therapeutics, Inc. Common Stock
VIRX
VIRX
Delisted
VIRX was delisted on the 3rd of February, 2025.
68 hedge funds and large institutions have $65.1M invested in Viracta Therapeutics, Inc. Common Stock in 2021 Q4 according to their latest regulatory filings, with 13 funds opening new positions, 15 increasing their positions, 22 reducing their positions, and 12 closing their positions.
New
Increased
Maintained
Reduced
Closed
more funds holding
Funds holding: →
more first-time investments, than exits
New positions opened: | Existing positions closed:
more funds holding in top 10
Funds holding in top 10: →
less repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
48% less capital invested
Capital invested by funds: $124M → $65.1M (-$59.3M)
58% less call options, than puts
Call options by funds: $143K | Put options by funds: $341K
Holders
68
Holding in Top 10
1
Calls
$143K
Puts
$341K
Top Buyers
| 1 | +$1.99M | |
| 2 | +$1.26M | |
| 3 | +$1.04M | |
| 4 |
Two Sigma Investments
New York
|
+$582K |
| 5 |
Renaissance Technologies
New York
|
+$422K |
Top Sellers
| 1 | -$5.85M | |
| 2 | -$3.6M | |
| 3 | -$2.07M | |
| 4 |
JPMorgan Chase & Co
New York
|
-$2.05M |
| 5 |
Janus Henderson Group
London,
United Kingdom
|
-$2M |